Overview

Study for Efficacy and Dose Escalation of AD313 + Atomoxetine (SEED)

Status:
Recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
The SEED study is designed to assess the safety and efficacy for Obstructive Sleep Apnea (OSA) of 3 escalating dose combinations of atomoxetine with AD313 compared to baseline and to atomoxetine alone.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Apnimed
Treatments:
Atomoxetine Hydrochloride